Sub Menu Area
Program
Contents Area
Scientific Program
ASGO 2019
"Optimal Gynecologic Cancer Care in Asia"
*Program is subject to change.
| Time | Program | Speaker | |
|---|---|---|---|
| [Symposium 3] Revised FIGO Stage of Cervix Cancer & Related Issues (90 min) | Chair: Neerja Bhatla (India) Co-chair: Jatupol Srisomboon (Thailand) |
||
| 08:30-08:45 | Validating new (2018) FIGO staging of cervix cancer | Kailash Narayan (Australia) | |
| 08:45-09:00 | Pathologic perspectives in revised FIGO | Hyojin Kim (Korea) | |
| 09:00-09:15 | Status of less-radical surgery in Japan | Takahide Arimoto (Japan) | |
| 09:15-09:30 | Predictive models for metastasis and recurrence after radical hysterectomy in patients with early-stage cervical cancer | Kittipat Charoenkwan (Thailand) | |
| 09:30-09:45 | Surgical staging in advanced stage | Chel Hun Choi (Korea) | |
| 09:45-10:00 | Discussion | ||
| [Symposium 4] Endometrial Cancer Update (90 min) | Chair: Duk-Soo Bae (Korea) Co-chair: Qi Zhou (China) |
||
| 08:30-08:50 | How to avoid futile LND in early stage endometrial cancer | Sokbom Kang (Korea) | |
| 08:50-09:10 | LND issues in endometrial cancer | Hidemichi Watari (Japan) | |
| 09:10-09:30 | Molecular classification of endometrial cancer | Kidong Kim (Korea) | |
| 09:30-09:50 | Preservation of ovary in the management of endometrial carcinoma | Kun Song (China) | |
| 09:50-10:00 | Discussion | ||
| [Education Session 3] ERAS (35 min) | Chair: Dae-Sik Seo (Korea) | ||
| 08:30-08:45 | Pre and postoperative management in gynecologic cancer surgery with planned bowel resection | Jung Myun Kwak (Korea) | |
| 08:45-09:00 | Pain management and anesthetic issue | Jin-Tae Kim (Korea) | |
| 09:00-09:05 | Discussion | ||
| [Special Session 1] Molecular Dissection of Ovarian Clear Cell Carcinoma (50 min) | Chair: Aikou Okamoto (Japan) Co-chair: Jeong-Won Lee (Korea) |
||
| 09:10-09:25 | Ovarian clear cell carcinoma: molecular characterization of sensitivity to platinum-based chemotherapy | Masataka Takenaka (Japan) | |
| 09:25-09:40 | Molecular profiling of ovarian clear cell carcinomas: implications for therapy | Ruby Huang (Taiwan) | |
| 09:40-09:55 | Genomics to immunotherapy of ovarian clear cell carcinoma | Katsutoshi Oda (Japan) | |
| 09:55-10:00 | Discussion | ||
| [Plenary Session 2] Surgical Issues in Gynecologic Oncology Field (110 min) | Chair: Daisuke Aoki (Japan) Co-chair: Young-Tae Kim (Korea) |
||
| 2nd debulking in epithelial ovarian cancer | 10:20-10:35 | Surgery for recurrent ovarian cancer. Evidence from DESKTOP series and others | Andreas du Bois (Germany) |
| 10:35-10:50 | GOG 213 surgical part | Robert Coleman (USA) | |
| 10:50-11:05 | Selection criteria and principles for 2nd debulking surgery: expert point of view | Dennis Chi (USA) | |
| 11:05-11:15 | Discussion | ||
| Surgical approach in early stage cervical cancer after LACC | 11:15-11:30 | Real problems of laparoscopic radical hysterectomy | Joo-Hyun Nam (Korea) |
| 11:30-11:45 | Asian viewpoint | Mikio Mikami (Japan) | |
| 11:45-12:00 | American and the other world viewpoint | Mario Leitao (USA) | |
| 12:00-12:10 | Discussion | ||
| [Special Symposium 2] (20 min) | Chair: Seob Jeon (Korea) | ||
| 12:20-12:40 | Role of bevacizumab in ovarian cancer & evolution as backbone of novel combination | Mansoor R Mirza (Denmark) | |
| [Plenary Session 3] PAPRi, Immuno-Oncology and Beyond (90 min) | Chair: Seung Cheol Kim (Korea) Co-chair: Xing Xie (China) |
||
| 13:10-13:30 | PARP inhibition in ovarian cancer: is it time for a paradigm shift? | Richard Penson (USA) | |
| 13:30-13:50 | Prevalence of BRCA mutation and real world experience of PAPRi | Byoung-Gie Kim (Korea) | |
| 13:50-14:10 | Biomarkers for immunotherapy usage in gynecologic cancer | Wei Zhou (USA) | |
| 14:10-14:30 | Novel and emerging agents under development for gynecologic cancers | Wen Yee Chay (Singapore) | |
| 14:30-14:40 | Discussion | ||
| [Symposium 5] Hereditary Breast and Ovarian Cancer in Asia (90 min) | Chair: Takayuki Enomoto (Japan) Co-chair: Wen-Fang Cheng (Taiwan) |
||
| 15:00-15:20 | Establishing BRCA consortium in Asia | Sung-Won Kim (Korea) | |
| 15:20-15:40 | Strategies of genetic test and counseling in Asia | Masayuki Sekine (Japan) | |
| 15:40-16:00 | Clinical impact of hereditary predisposition in gynecologic cancer | Myong-Cheol Lim (Korea) | |
| 16:00-16:20 | A need of Asian guidelines for the management of BRCA carrier | Arb-aroon Lertkhachonsuk (Thailand) | |
| 16:20-16:30 | Discussion | ||
| [Symposium 6] MIS in gynecologic cancer management (90 min) | Chair: Nobuo Yaegashi (Japan) Co-chair: Soo Young Hur (Korea) |
||
| 15:00-15:15 | Sentinel lymph node biopsy in cervical and vulvar cancer | Mario Leitao (USA) | |
| 15:15-15:30 | Robotic approach for high-risk endometrial cancer | Jiheum Paek (Korea) | |
| 15:30-15:45 | Sentinel lymph node staging experience in Thailand | Nuttavut Kantathavorn (Thailland) | |
| 15:45-16:00 | Two-step sentinel lymph node mapping strategy in endometrial cancer | Sang-Wun Kim (Korea) | |
| 16:00-16:15 | Current role of minimally invasive surgery for ovarian cancer | Jeong-Yeol Park (Korea) | |
| 16:15-16:30 | Discussion | ||
| Ovarian Cancer Roundtable Session of Chinese Gynecologic Oncologists (15:00-17:00) | |||
| 15:00-15:10 | Opening | ||
| Part 1 | Jihong Liu (China) | ||
| 15:10-15:40 | Cornerstone recent advances in surgery of ovarian cancer | Jianqing Zhu (China) | |
| 15:40-16:00 | Discussion | Discussion Leader: Yang Xiang (China) |
|
| Part 2 | Qi Zhou (China) | ||
| 16:00-16:30 | Milestone · advances in targeted therapy in ovarian cancer | Rutie Yin (China) | |
| 16:30-16:50 | Discussion | Discussion Leader: Yang Xiang (China) |
|
| 16:50-17:00 | Closing | Xing Xie (China), Rongyu Zang (China) |
|
| [Oral 3] TR in Ovarian Cancer (90 min) | Chair: Sarikapan Wilailak (Thailand) Co-chair: Ting-Chang Chang (Taiwan) |
||
| 15:00-15:10 | Antitumor effect of FGFR inhibitor AZD4547 in ovarian cancer cells | Tae-Kyu Jang (Korea) | |
| 15:10-15:20 | Survival prognosis of uterine-preserving surgery on stage I primary mucinous epithelial ovarian carcinoma | Kaname Uno (Japan) | |
| 15:20-15:30 | YAP silencing using dobutamine-PLGA nanoparticle as a new therapeutic strategy for ovarian cancer | Ju-Won Roh (Korea) | |
| 15:30-15:40 | Tyrosine kinase receptor TIE-1 mediates cell growth by regulating PI3K/Akt signaling pathway in PI3K-high-expressing ovarian cancer | Xuewei Zhang (Japan) | |
| 15:40-15:50 | First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors | Wen Yee Chay (Singapore) | |
| 15:50-16:00 | The roles of androgen receptor in chemosensitivity in serous ovarian cancer | Hung-Chun Fu (Taiwan) | |
| 16:00-16:10 | Cancer stem cell (CD133, CD44 and ALDH1A1) markers as prognostic factors on epithelial ovarian cancer | Nugraha Pelupessy (Indonesia) | |
| 16:10-16:20 | Low expression of gamma-glutamyl transpeptidase 1 is an independent poor prognostic factor associated with up-regulation of immune suppressive genes and EMT-related genes in ovarian clear cell carcinoma | Hiroshi Asano (Japan) | |
| 16:20-16:30 | The role Of Akt2, and CA-125 serum levels as predictors for cytoreduction in epithelial ovarian cancer surgery | Yudi Mulyana Hidayat (Indonesia) | |
| [Education Session 4] Surgical and Molecular Tumor Board (90 min) | Chair: Sang Young Ryu (Korea) Co-chair: Xiaoping Li (China) |
||
| Case Presentation 1 | 16:50-17:00 | Case presentation: cervix cancer | U Chul Ju (Korea) |
| 17:00-17:15 | Comments on of the cervical cancer management | Hung-Cheng Lai (Taiwan) | |
| 17:15-17:20 | Discussion | ||
| Case Presentation 2 | 17:20-17:30 | Case presentation: endometrial cancer | Yiqin Wang (China) |
| 17:30-17:45 | Comments on various aspects of the case management | Janice Kwon (Canada) | |
| 17:45-17:50 | Discussion | ||
| Case Presentation 3 | 17:50-18:00 | Case presentation: epithelial ovarian cancer | Won-Kyo Shin (Korea) |
| 18:00-18:15 | Comments on various aspects of the case management | Masaki Mandai (Japan) | |
| 18:15-18:20 | Discussion | ||
| [Oral 4] Issues in Surgical Treatment (80 min) | Chair: Kung-Liahng Wang (Taiwan) Co-Chair: Yoon-Soon Lee (Korea) |
||
| 16:50-17:00 | Risk factors for lymph node metastasis according to LVSI in apparent uterine-confined endometrial cancer | Joo-Hyuk Son (Korea) | |
| 17:00-17:10 | Development of novel diagnosis method of uterine cancer using lymph node metastasis predictive biomarker for more personalized lymphadenectomy | Emiko Yoshida (Japan) | |
| 17:10-17:20 | Comparison of ROMA algorithm and CA 125 as tools for discriminate benign ovarian tumor and early stage ovarian cancer according to imaging tumor subtypes that connected to postoperative histopathologic findings | Youngjae Lee (Korea) | |
| 17:20-17:30 | Inadvertent ovarian malignancy following operative laparoscopy of adnexal masses: university malaya medical centre experience | Muhammad Asyaraf Azizan (Malaysia) | |
| 17:30-17:40 | Analysis of factors influencing the recurrence and fertility outcomes of ovarian borderline tumors | Zhengmao Zhang (China) | |
| 17:40-17:50 | The effect of pelvic and para-aortic lymphadenectomy for clinically-apparent stage I endometrioid epithelial ovarian carcinoma | Masato Yoshihara (Japan) | |
| 17:50-18:00 | Oncologic outcomes after secondary surgery in recurrent clear-cell carcinoma of the ovary | Shohei Iyoshi (Japan) | |
| 18:00-18:10 | Knowledge, attitude and practices of gynecologists in a tertiary hospital on preoperative bowel preparation | Romelyn Imperio-Onglao (Philippines) | |
| [Special Session 2] ASGO-AOGIN Joint Session: How to Collaborate to Eliminate Cervical Cancer in Asia-Pacific Region (90 min) | Chair: EH Tay (Singapore) Co-chair: Young-Tak Kim (Korea) |
||
| 16:50-17:10 | Elimination of cervical cancer: global overview and prospects for Asia | Neerja Bhatla (India) | |
| 17:10-17:30 | VIA with picture as one option strategy in increasing the cervical cancer screening coverage in low resource setting area | Dwiana Ocviyanti (Indonesia) | |
| 17:30-17:50 | HPV test as a primary cervical cancer screening | Warner Huh (USA) | |
| 17:50-18:10 | Cost-effectiveness of primary HPV test and triage test in cervical cancer screening | Wichai Termrungruanglert (Thailand) | |
| 18:10-18:20 | Discussion | ||